Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Sarah Longwell, Publisher for The Bulwark and Robert Armstrong, US Financial Commentator for The Financial Times join Nicolle Wallace on Deadline White House to discuss who appear to be bearing the ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca and ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology.

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

That could be the case for the Chicago Bears in the 2025 NFL Draft, and not just in the first round. Their three biggest needs could be at positions with the most value when they're on the clock ...

Afternoon egg hunts and the Cubs game were interrupted Sunday by a bout of heavy rain across the Chicago area, which eased up in the late afternoon before more stormy weather overnight.

Anyone with outdoor plans for the Easter observance could be dodging raindrops or even scattered thunderstorms in the Chicago area. According to the NBC 5 Storm Team, scattered showers and even a ...

Illumina Inc. and Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, announced a collaboration to accelerate clinical adoption of ...